MST-312 induces G2/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-κB pathway

Tumor Biology

Volumn 36, Issue 11, 2015, Pages 8425-8437

  Fatemi, Ahmad ^a   Safa, Majid ^a   Kazemi, Ahmad ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

APL; MST 312; NF B; Telomerase

Indexed keywords

CASPASE; DNA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MST 312; MYC PROTEIN; PROTEIN BCL 2; SURVIVIN; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CATECHIN; EPIGALLOCATECHIN GALLATE; TERT PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BCL 2 GENE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; GENE PRODUCT; HTERT GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MCL 1 GENE; ONCOGENE C MYC; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SURVIVIN GENE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, PROMYELOCYTIC, ACUTE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BENZAMIDES; CATECHIN; CELL LINE, TUMOR; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TELOMERASE;

EID: 84949110713     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3575-z     Document Type: Article

References (48)

1. Stein EM, Tallman MS. Acute promyelocytic leukemia in children and adolescents. Acta Haematol. 2014;132(3-4):307–12.
2. Chen Z, Wang Z-Y, Chen S-J. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther. 1997;76(1):141–9.
3. Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007;92(1):81–94.
4. Fulda S. Evasion of apoptosis as a cellular stress response in cancer. International journal of cell biology. 2010;2010.
5. Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. BioMed research international. 2014;2014.
6. Verdun RE, Karlseder J. Replication and protection of telomeres. Nature. 2007;447(7147):924–31.
7. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2005;26(5):867–74.
8. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008;8(3):167–79.
9. Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci. 2013;38(9):426–34.
10. Chang S, DePinho RA. Telomerase extracurricular activities. Proc Natl Acad Sci. 2002;99(20):12520–2.
11. Martínez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer. 2011;11(3):161–76.
12. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol. 2003;5(5):474–9.
13. Xiang H, Wang J, Mao Y, Liu M, Reddy VN, Li D. Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathway. Oncogene. 2002;21(23):3784–91.
14. Kirkpatrick KL, Newbold RF, Mokbel K. The mRNA expression of hTERT in human breast carcinomas correlates with VEGF expression. J Carcinogen. 2004;3(1):1.
15. Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V, et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene. 2003;22(1):131–46.
16. Lee J, Sung Y, Cheong C, Choi Y, Jeon H, Sun W, et al. TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene. 2008;27(26):3754–60.
17. Massard C, Zermati Y, Pauleau A, Larochette N, Metivier D, Sabatier L, et al. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene. 2006;25(33):4505–14.
18. Rahman R, Latonen L, Wiman KG. hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene. 2004;24(8):1320–7.
19. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, et al. Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol. 2012;14(12):1270–81.
20. Park J-I, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 2009;460(7251):66–72.
21. Jost PJ, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7):2700–7.
22. Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor κB as a target for new drug development in myeloid malignancies. Haematologica. 2007;92(9):1224–9.
23. Baud V, Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33–40.
24. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-κB. Oncogene. 2006;25(51):6800–16.
25. Nagel D, Vincendeau M, Eitelhuber A, Krappmann D. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies. Oncogene. 2014.
26. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011–5.
27. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999;13(18):2388–99.
28. Herbert B-S, Pitts A, Baker S, Hamilton S, Wright W, Shay J, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci. 1999;96(25):14276–81.
29. Röth A, Dürig J, Himmelreich H, Bug S, Siebert R, Dührsen U, et al. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia. 2007;21(12):2456–62.
30. Blackburn EH. Telomere states and cell fates. Nature. 2000;408(6808):53–6.
31. Ghaffari S, Shayan-Asl N, Jamialahmadi A, Alimoghaddam K, Ghavamzadeh A. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Annals of Oncology. 2008:mdn394.
32. Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K, et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-199. Mol Cancer Ther. 2002;1(9):657–65. Supported in part by a grant-in-aid for scientific research on priority areas from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
33. Gurung RL, Lim HK, Venkatesan S, Lee PSW, Hande MP. Targeting DNA-PKcs and telomerase in brain tumour cells. Mol Cancer. 2014;13(1):232.
34. Serrano D, Bleau A-M, Fernandez-Garcia I, Fernandez-Marcelo T, Iniesta P, Ortiz-de-Solorzano C, et al. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Mol Cancer. 2011;10(96).
35. Collins K. Physiological assembly and activity of human telomerase complexes. Mech Ageing Dev. 2008;129(1):91–8.
36. Wojtyla A, Gladych M, Rubis B. Human telomerase activity regulation. Mol Biol Rep. 2011;38(5):3339–49.
37. Cerni C. Telomeres, telomerase, and myc. An update. Mutation Res/Rev Mutation Res. 2000;462(1):31–47.
38. 2 hepatoma cell line. Eur J Pharmacol. 2011;672(1):113–20.
39. Yin L, Hubbard AK, Giardina C. NF-κB regulates transcription of the mouse telomerase catalytic subunit. J Biol Chem. 2000;275(47):36671–5.
40. Wang JC, Bennett MR. Nuclear factor-κΒ–mediated regulation of telomerase the Myc link. Arterioscler Thromb Vasc Biol. 2010;30(12):2327–8.
41. Olaussen KA, Dubrana K, Domont J, Spano J-P, Sabatier L, Soria J-C. Telomeres and telomerase as targets for anticancer drug development. Crit Rev Oncol/Hematol. 2006;57(3):191–214.
42. Shay JW. Telomerase as a target for cancer therapeutics. Gene-based therapies for cancer: Springer; 2010. p. 231-49.
43. Wong VC, Ma J, Hawkins CE. Telomerase inhibition induces acute ATM-dependent growth arrest in human astrocytomas. Cancer Lett. 2009;274(1):151–9.
44. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat. 2006;96(1):73–81.
45. Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res. 2003;9(10):3794–800.
46. Mikami-Terao Y, Akiyama M, Yuza Y, Yanagisawa T, Yamada O, Yamada H. Antitumor activity of G-quadruplex–interactive agent TMPyP4 in K562 leukemic cells. Cancer Lett. 2008;261(2):226–34.
47. Calado RT, Chen J. Telomerase: not just for the elongation of telomeres. Bioessays. 2006;28(2):109–12.
48. Ding D, Xi P, Zhou J, Wang M, Cong Y-S. Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-κB-dependent transcription. FASEB J. 2013;27(11):4375–83.